ABT vs. GILD: A Head-to-Head Stock Comparison
Updated onHere’s a clear look at ABT and GILD, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.
Company Profile
| Symbol | ABT | GILD |
|---|---|---|
| Company Name | Abbott Laboratories | Gilead Sciences, Inc. |
| Country | United States | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry | Health Care Equipment & Supplies | Biotechnology |
| Market Capitalization | 229.51 billion USD | 141.64 billion USD |
| Exchange | NYSE | NasdaqGS |
| Listing Date | March 17, 1980 | January 22, 1992 |
| Security Type | Common Stock | Common Stock |
Historical Performance
This chart compares the performance of ABT and GILD by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.
Historical Performance at a Glance
| Symbol | ABT | GILD |
|---|---|---|
| 5-Day Price Return | 0.47% | -3.25% |
| 13-Week Price Return | 0.28% | 6.94% |
| 26-Week Price Return | -0.20% | 6.04% |
| 52-Week Price Return | 17.64% | 50.40% |
| Month-to-Date Return | 4.50% | 1.66% |
| Year-to-Date Return | 16.59% | 23.58% |
| 10-Day Avg. Volume | 5.40M | 5.73M |
| 3-Month Avg. Volume | 6.54M | 7.68M |
| 3-Month Volatility | 24.04% | 29.22% |
| Beta | 0.70 | 0.37 |
Profitability
Return on Equity (TTM)
ABT
29.93%
Health Care Equipment & Supplies Industry
- Max
- 34.53%
- Q3
- 19.38%
- Median
- 9.52%
- Q1
- 4.86%
- Min
- -7.58%
In the upper quartile for the Health Care Equipment & Supplies industry, ABT’s Return on Equity of 29.93% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
GILD
32.97%
Biotechnology Industry
- Max
- 77.14%
- Q3
- 10.76%
- Median
- -20.08%
- Q1
- -42.71%
- Min
- -119.20%
In the upper quartile for the Biotechnology industry, GILD’s Return on Equity of 32.97% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.
Net Profit Margin (TTM)
ABT
32.43%
Health Care Equipment & Supplies Industry
- Max
- 23.34%
- Q3
- 13.06%
- Median
- 9.53%
- Q1
- 5.96%
- Min
- -3.87%
ABT’s Net Profit Margin of 32.43% is exceptionally high, placing it well beyond the typical range for the Health Care Equipment & Supplies industry. This demonstrates outstanding operational efficiency and a strong competitive advantage in converting revenue into profit.
GILD
21.87%
Biotechnology Industry
- Max
- 59.44%
- Q3
- 16.21%
- Median
- -11.49%
- Q1
- -167.42%
- Min
- -409.07%
A Net Profit Margin of 21.87% places GILD in the upper quartile for the Biotechnology industry, signifying strong profitability and more effective cost management than most of its peers.
Operating Profit Margin (TTM)
ABT
17.34%
Health Care Equipment & Supplies Industry
- Max
- 29.44%
- Q3
- 17.80%
- Median
- 13.95%
- Q1
- 8.73%
- Min
- -3.56%
ABT’s Operating Profit Margin of 17.34% is around the midpoint for the Health Care Equipment & Supplies industry, indicating that its efficiency in managing core business operations is typical for the sector.
GILD
27.89%
Biotechnology Industry
- Max
- 60.62%
- Q3
- 20.76%
- Median
- -12.41%
- Q1
- -181.14%
- Min
- -482.02%
An Operating Profit Margin of 27.89% places GILD in the upper quartile for the Biotechnology industry. This signals a strong ability to translate revenue into operating profit, outperforming most of its competitors in core business efficiency.
Profitability at a Glance
| Symbol | ABT | GILD |
|---|---|---|
| Return on Equity (TTM) | 29.93% | 32.97% |
| Return on Assets (TTM) | 17.41% | 11.19% |
| Net Profit Margin (TTM) | 32.43% | 21.87% |
| Operating Profit Margin (TTM) | 17.34% | 27.89% |
| Gross Profit Margin (TTM) | 56.20% | 78.53% |
Financial Strength
Current Ratio (MRQ)
ABT
1.82
Health Care Equipment & Supplies Industry
- Max
- 4.90
- Q3
- 3.05
- Median
- 2.14
- Q1
- 1.49
- Min
- 0.86
ABT’s Current Ratio of 1.82 aligns with the median group of the Health Care Equipment & Supplies industry, indicating that its short-term liquidity is in line with its sector peers.
GILD
1.32
Biotechnology Industry
- Max
- 19.31
- Q3
- 9.38
- Median
- 4.54
- Q1
- 2.45
- Min
- 0.76
GILD’s Current Ratio of 1.32 falls into the lower quartile for the Biotechnology industry. This indicates a tighter liquidity situation and a more constrained capacity to handle short-term debt than many of its competitors.
Debt-to-Equity Ratio (MRQ)
ABT
0.27
Health Care Equipment & Supplies Industry
- Max
- 1.49
- Q3
- 0.71
- Median
- 0.45
- Q1
- 0.14
- Min
- 0.00
ABT’s Debt-to-Equity Ratio of 0.27 is typical for the Health Care Equipment & Supplies industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.
GILD
1.27
Biotechnology Industry
- Max
- 1.35
- Q3
- 0.64
- Median
- 0.09
- Q1
- 0.00
- Min
- 0.00
GILD’s leverage is in the upper quartile of the Biotechnology industry, with a Debt-to-Equity Ratio of 1.27. While this approach can boost equity growth, it also exposes the company to greater financial vulnerability.
Interest Coverage Ratio (TTM)
ABT
38.30
Health Care Equipment & Supplies Industry
- Max
- 58.29
- Q3
- 25.56
- Median
- 9.06
- Q1
- 3.60
- Min
- -28.92
ABT’s Interest Coverage Ratio of 38.30 is in the upper quartile for the Health Care Equipment & Supplies industry, signifying a strong and healthy capacity to meet its interest payments from operating profits.
GILD
1.71
Biotechnology Industry
- Max
- 72.37
- Q3
- 1.91
- Median
- -7.81
- Q1
- -63.90
- Min
- -153.80
GILD’s Interest Coverage Ratio of 1.71 is positioned comfortably within the norm for the Biotechnology industry, indicating a standard and healthy capacity to cover its interest payments.
Financial Strength at a Glance
| Symbol | ABT | GILD |
|---|---|---|
| Current Ratio (MRQ) | 1.82 | 1.32 |
| Quick Ratio (MRQ) | 1.14 | 0.89 |
| Debt-to-Equity Ratio (MRQ) | 0.27 | 1.27 |
| Interest Coverage Ratio (TTM) | 38.30 | 1.71 |
Growth
Revenue Growth
EPS Growth
Dividend
Dividend Yield (TTM)
ABT
1.73%
Health Care Equipment & Supplies Industry
- Max
- 4.05%
- Q3
- 1.76%
- Median
- 0.71%
- Q1
- 0.00%
- Min
- 0.00%
ABT’s Dividend Yield of 1.73% is consistent with its peers in the Health Care Equipment & Supplies industry, providing a dividend return that is standard for its sector.
GILD
3.98%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
GILD’s Dividend Yield of 3.98% is exceptionally high, placing it well above the typical range for the Biotechnology industry. While this may seem attractive, an unusually high yield can sometimes be a warning sign, reflecting a falling stock price or market concerns about the dividend’s sustainability.
Dividend Payout Ratio (TTM)
ABT
28.42%
Health Care Equipment & Supplies Industry
- Max
- 160.00%
- Q3
- 72.47%
- Median
- 27.49%
- Q1
- 0.00%
- Min
- 0.00%
ABT’s Dividend Payout Ratio of 28.42% is within the typical range for the Health Care Equipment & Supplies industry, suggesting a balanced approach between shareholder payouts and company reinvestment.
GILD
117.08%
Biotechnology Industry
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
At 117.08%, GILD’s Dividend Payout Ratio is exceptionally high, exceeding the typical range for the Biotechnology industry. While this provides a significant return to shareholders, it may limit funds for reinvestment and could be difficult to sustain.
Dividend at a Glance
| Symbol | ABT | GILD |
|---|---|---|
| Dividend Yield (TTM) | 1.73% | 3.98% |
| Dividend Payout Ratio (TTM) | 28.42% | 117.08% |
Valuation
Price-to-Earnings Ratio (TTM)
ABT
16.47
Health Care Equipment & Supplies Industry
- Max
- 73.48
- Q3
- 51.69
- Median
- 34.31
- Q1
- 25.74
- Min
- 11.47
In the lower quartile for the Health Care Equipment & Supplies industry, ABT’s P/E Ratio of 16.47 suggests the stock may be undervalued compared to its peers, potentially presenting an attractive entry point for investors.
GILD
23.57
Biotechnology Industry
- Max
- 60.14
- Q3
- 38.17
- Median
- 29.01
- Q1
- 15.12
- Min
- 0.00
GILD’s P/E Ratio of 23.57 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.
Price-to-Sales Ratio (TTM)
ABT
5.34
Health Care Equipment & Supplies Industry
- Max
- 9.53
- Q3
- 5.26
- Median
- 3.39
- Q1
- 2.13
- Min
- 0.00
ABT’s P/S Ratio of 5.34 is in the upper echelon for the Health Care Equipment & Supplies industry. This means the company is valued richly on its revenue stream compared to its peers, suggesting the stock is priced for a high level of future performance.
GILD
5.15
Biotechnology Industry
- Max
- 76.98
- Q3
- 36.53
- Median
- 9.49
- Q1
- 4.49
- Min
- 0.00
GILD’s P/S Ratio of 5.15 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.
Price-to-Book Ratio (MRQ)
ABT
4.68
Health Care Equipment & Supplies Industry
- Max
- 10.85
- Q3
- 5.98
- Median
- 3.48
- Q1
- 2.43
- Min
- 0.69
ABT’s P/B Ratio of 4.68 is within the conventional range for the Health Care Equipment & Supplies industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
GILD
7.01
Biotechnology Industry
- Max
- 20.53
- Q3
- 9.76
- Median
- 4.77
- Q1
- 2.49
- Min
- 0.59
GILD’s P/B Ratio of 7.01 is within the conventional range for the Biotechnology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.
Valuation at a Glance
| Symbol | ABT | GILD |
|---|---|---|
| Price-to-Earnings Ratio (TTM) | 16.47 | 23.57 |
| Price-to-Sales Ratio (TTM) | 5.34 | 5.15 |
| Price-to-Book Ratio (MRQ) | 4.68 | 7.01 |
| Price-to-Free Cash Flow Ratio (TTM) | 33.99 | 16.29 |